Photodynamic Therapy of Superficial Basal Cell Carcinoma with 5-Aminolevulinic Acid with Dimethylsulfoxide and Ethylendiaminetetraacetic Acid: A Comparison of Two Light Sources

Abstract The aim of this prospective randomized study was to compare the clinical and cosmetic outcome of superficial basal cell carcinomas (BCC), using either laser or broadband halogen light, in photodynamic therapy with topical 5-aminolevulinic acid (ALA). A total of 83 patients with 245 superficial BCC were included in the study. Standard treatment involved 15 min of local pretreatment with 99% dimethylsulfoxide (DMSO) before topical application of 20% ALA with DMSO (2%) and ethylendiaminetetraacetic acid (2%) as cofactors for 3 h before light exposure with either laser or a broadband lamp (BL). A complete response was achieved in 95 lesions (86%) in the laser group and 110 lesions (82%) in the BL group 6 months after treatment. Of these, 80 lesions (84%) in the laser group and 101 lesions (92%) in the lamp group were independently evaluated to have an excellent or good cosmetic post-treatment score. No serious adverse events were reported. This study shows that there is no statistical significant difference in cure the rate (P = 0.49) and the cosmetic outcome (P = 0.075) with topical application of a modified ALA-cream between light exposure from a simple BL with continuous spectrum (570–740 nm) or from a red-light laser (monochromatic 630 nm). Cost and safety are further elements in favor of the BL in this setting.

[1]  S. Gibson,et al.  Effect of 5‐AmJnolevulinic Acid on Protoporphyrin IX Accumulation in Tumor Cells Transfected with Plasmids Containing Porphobilinogen Deaminase DNA , 1999, Photochemistry and photobiology.

[2]  S. Gibson,et al.  δ-Aminolaevulinic acid-induced photodynamic therapy inhibits protoporphyrin IX biosynthesis and reduces subsequent treatment efficacy in vitro , 1999, British Journal of Cancer.

[3]  Z. Malik,et al.  The kinetics of protoporphyrin fluorescence during ALA-PDT in human malignant skin tumors. , 1997, Cancer letters.

[4]  J Moan,et al.  5‐Aminolevulinic acid‐based photodynamic therapy , 1997, Cancer.

[5]  C. Whitehurst,et al.  Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease , 1996, The British journal of dermatology.

[6]  H. Wulf,et al.  Photodynamic therapy with 5‐aminolevulinic acid in the treatment of actinic cheilitis , 1996, The British journal of dermatology.

[7]  F. Roberts Comments on 'Problems associated with the use of broad-band illumination sources for photodynamic therapy'. , 1996, Physics in medicine and biology.

[8]  Johan Emelian Moan,et al.  Measurements of light penetration into human tissues in vivo , 1996, European Conference on Biomedical Optics.

[9]  M. Stringer Problems associated with the use of broad-band illumination sources for photodynamic therapy. , 1995, Physics in medicine and biology.

[10]  A. Oseroff,et al.  THE ROLE OF TRANSFERRIN RECEPTOR (CD71) IN PHOTODYNAMIC THERAPY OF ACTIVATED AND MALIGNANT LYMPHOCYTES USING THE HEME PRECURSOR δ‐AMINOLEVULINIC ACID (ALA) , 1995, Photochemistry and photobiology.

[11]  S. Iinuma,et al.  A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin. , 1994, British Journal of Cancer.

[12]  M Landthaler,et al.  A possible new incoherent lamp for photodynamic treatment of superficial skin lesions. , 1994, Acta dermato-venereologica.

[13]  S. G. Bown,et al.  Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phthalocyanine and 5-aminolaevulinic acid. , 1992, British Journal of Cancer.

[14]  J Hanania,et al.  The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitization of human K562 leukemic cells. , 1992, Cancer letters.

[15]  J C Kennedy,et al.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.

[16]  D. Phillips,et al.  Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model. , 1992, British Journal of Cancer.

[17]  J. Kennedy,et al.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. , 1990, Journal of photochemistry and photobiology. B, Biology.

[18]  K. Ball Photodynamic therapy of malignant tumors. , 1987, Today's OR nurse.

[19]  Robert E. Anderson,et al.  Hematoporphyrin derivative: Quantitative uptake in dimethylhydrazine‐induced murine colorectal carcinoma , 1983, Journal of surgical oncology.

[20]  T J Dougherty,et al.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. , 1976, Cancer research.

[21]  J Moan,et al.  The Biophysical Foundations of Photodynamic Therapy , 1998, Endoscopy.

[22]  H Kerl,et al.  Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? , 1993, Journal of the American Academy of Dermatology.